Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Anti-IL-17A Monoclonal Antibody

Ixekizumab

Brand names: Taltz

Ixekizumab is a monoclonal antibody targeting interleukin-17A, given by subcutaneous injection. It is used for moderate to severe plaque psoriasis, psoriatic arthritis and axial spondyloarthritis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively binds and neutralises interleukin-17A, a key cytokine driving the inflammation underlying psoriatic and spondyloarthritic disease.

Prescribing in practice

  • Avoid in active infection and screen for tuberculosis before starting, as IL-17 inhibition increases susceptibility to infection.
  • It can cause or exacerbate inflammatory bowel disease, so use with caution and monitor in patients with a relevant history.
  • Avoid live vaccines during treatment and review vaccination status beforehand.

Monitoring

Monitor for infection, including mucocutaneous candidiasis, and for new or worsening inflammatory bowel symptoms during therapy.

Counselling the patient

  • Report signs of infection such as fever, or persistent sore mouth or throat suggesting thrush.
  • Report new or worsening abdominal pain, diarrhoea or blood in the stool.
  • Patients or carers can be trained to give the injection at home using the prefilled device.

Evidence & guidelines

NICE recommends ixekizumab for plaque psoriasis and psoriatic arthritis within defined treatment criteria.

Reference: NICE TA442; UNCOVER trials; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways